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The high-energy sulfate donor 3-phosphoadenosine-5-
phosphosulfate (PAPS), generated by human PAPS synthase
isoforms PAPSS1 and PAPSS2, is required for all human sulfa-
tion pathways. Sulfotransferase SULT2A1 uses PAPS for
sulfation of the androgen precursor dehydroepiandrosterone
(DHEA), thereby reducing downstream activation of DHEA
to active androgens. Human PAPSS2 mutations manifest with
undetectable DHEA sulfate, androgen excess, and metabolic
disease, suggesting that ubiquitous PAPSS1 cannot compensate
for deficient PAPSS2 in supporting DHEA sulfation. In knock-
down studies in human adrenocortical NCI-H295R1 cells, we
found that PAPSS2, but not PAPSS1, is required for efficient
DHEA sulfation. Specific APS kinase activity, the rate-limiting
step in PAPS biosynthesis, did not differ between PAPSS1 and
PAPSS2. Co-expression of cytoplasmic SULT2A1 with a cyto-
plasmic PAPSS2 variant supported DHEA sulfation more
efficiently than co-expression with nuclear PAPSS2 or nuclear/
cytosolic PAPSS1. Proximity ligation assays revealed protein–
protein interactions between SULT2A1 and PAPSS2 and, to a
lesser extent, PAPSS1. Molecular docking studies showed a
putative binding site for SULT2A1 within the PAPSS2 APS
kinase domain. Energy-dependent scoring of docking solutions
identified the interaction as specific for the PAPSS2 and
SULT2A1 isoforms. These findings elucidate the mechanistic
basis for the selective requirement for PAPSS2 in humanDHEA
sulfation.
Sulfation pathways are a vital part of human physiology,
encompassing the central triad of sulfate activation, transfer,
and removal (1, 2). Many sulfotransferases ensure substrate
specificity of sulfation; the 62 human sulfotransferase genes only
have 46 direct counterparts in the mouse genome (2, 3).
In contrast, 3-phosphoadenosine-5-phosphosulfate (PAPS)2
synthases, the enzymes responsible for sulfate activation, are rep-
resented by only two genes in humans, PAPSS1 and PAPSS2 (4).
This gene pair is evolutionary conserved in all vertebrate genomes
investigated so far; RNA splice forms and additional teleost-spe-
cific gene duplications of PAPSS2 are the only exceptions (4).
The primary role of PAPS synthases is to provide the many
and diverse sulfotransferases with the high-energy sulfate
donor PAPS. PAPS availability is generally the limiting factor in
this system (5), due to the high energetic cost of PAPS biosyn-
thesis. First, nucleophilic sulfate needs to attack the -phos-
phorus of ATP, catalyzed by ATP sulfurylase, resulting in
the formation of APS (adenosine 5-phosphosulfate) and the
release of pyrophosphate (6). This reaction lies heavily on the
educt side, with an equilibrium constant for APS formation of
108 (7); a fact exploited in pyrosequencing (8). To pull the
reaction toward product formation, pyrophosphatases swiftly
cleave the pyrophosphate and APS kinase phosphorylates APS
at its ribose 3 position, resulting in the formation of PAPS (6).
Once PAPS is used in sulfation reactions, the remaining bis-
phosphorylated nucleotide PAP (3-phosphoadenosine-5-
phosphate) needs to be cleaved by dedicated PAP phosphatases
(9, 10). In animal genomes, ATP sulfurylase and APS kinase are
fused to the above mentioned bifunctional PAPS synthases (4,
11). The phosphorylation of APS by APS kinase is regarded the
rate-limiting step of overall PAPS biosynthesis (6, 12).
PAPS synthases 1 and 2 are very similar enzyme isoforms
with 78% amino acid identity (4), but with an unknown degree
of functional overlap. The clinical phenotype of human loss-of-
function mutations in the gene encoding PAPSS2 have sug-
gested differential roles for PAPSS1 and PAPSS2 in human sul-
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fation pathways (2, 13, 14). InactivatingPAPSS2mutations have
been reported to present with skeletal malformations, specifi-
cally variable phenotypes of spondyloepimetaphyseal dysplasia
(14, 15), and with biochemical and clinical evidence of andro-
gen excess (13, 14). Sulfation of the androgen precursor dehy-
droepiandrosterone (DHEA) reduces the availability of nonsul-
fated DHEA for downstream conversion to androgens. Hence,
impaired DHEA sulfation results in a higher rate of androgen
activation and clinically in androgen excess phenotypes such as
polycystic ovary syndrome (13, 14, 16). Crucially, the pheno-
type of human PAPSS2 deficiency proves that with regard to
DHEA sulfation and bone and chondrocyte development,
human PAPSS1, the gene encoding the only other PAPS syn-
thase, appears not to be able to compensate for the loss of
PAPSS2 gene function.
There has been considerable debate about the cause of the
divergent functions of the two PAPS synthase isoforms. Differ-
ences in subcellular localization have been suggested as an
underlying mechanism, with PAPSS1 reported as nuclear pro-
tein and PAPSS2 as primarily located in the cytoplasm (17).
However, this was recognized as oversimplification as both
enzymes actively shuttle between nucleus and cytoplasm,
guided by conserved nuclear localization and nuclear export
signals (18). Another aspect was an apparent difference in spe-
cific enzymatic activity. When assayed as pseudo one-step
enzymes, PAPSS2 was reported to display a much higher
kcat/Km value than PAPSS1 (19). When assaying only the rate-
limiting step of overall PAPS biosynthesis, the APS kinase-cat-
alyzed reaction, this difference was no longer observed (20).
Differences in tissue-specific distribution of the two PAPS syn-
thases have also been reported (13, 19, 21). Nevertheless, none
of those studies could sufficiently explain why the PAPSS1 gene
cannot compensate for the loss of PAPSS2 due to inactivating
PAPSS2mutations.
Here we report experimental evidence for nonoverlapping
functionality of PAPSS1 and PAPSS2 with regard to DHEA sul-
fation by SULT2A1 (Fig. 1A). Proximity ligation assays (PLAs)
detect a novel protein–protein interaction between SULT2A1
and PAPSS2 and molecular docking suggests SULT2A1 con-
tacts the APS kinase domain of PAPSS2. This newly described
protein–protein interaction, specific to the PAPSS2 and
SULT2A1 isoforms, may guide the directionality of sulfation
pathways in tissues with equal expression of PAPS synthases
and high expression levels of various sulfotransferases.
Results
PAPSS2 is functionally required for DHEA sulfation in a human
adrenocortical cell line
The adrenal cortex is a major site of DHEA sulfation. We
used human adrenocortical NCI-H295R1 cells, whichwe found
to express high levels of SULT2A1 mRNA (CT value 13.4 
1.3 relative to 18S rRNA, S.D., see also Table S1) and almost
identical mRNA levels of PAPSS1 and PAPSS2 (CT values
16.1 0.8 and 15.8 0.9, respectively).We separately targeted
SULT2A1 and both PAPS synthase isoforms by siRNA-
mediated knockdown, achieving knockdown efficiencies of
up to 90% at mRNA (Fig. 1B) and protein levels (Fig. 1C). We
Figure 1. Knockdown of components of the DHEA sulfation pathway. A,
schematic representation of theDHEA sulfation pathway. Activated sulfate in
the form of PAPS is produced by either PAPSS1 or PAPSS2 and then used
by the sulfotransferase SULT2A1 to convert DHEA to DHEAS. B and C,
siRNA-mediated knockdown of SULT2A1, PAPSS1, or PAPSS2 in adrenocorti-
cal NCI-H295R1 cells was verified by real-time PCR and Western blotting. A
scrambled oligonucleotide served as control (ctrl). Real-time PCR data nor-
malized to 18S rRNA, fold-change relative to that control. Densitometric
quantificationofWesternblots revealed knockdownefficiencies of up to 90%
on the protein level. Double bandswere interpreted as degradation products
and jointly analyzed.D, DHEA sulfationwas assayed for all knockdownsmen-
tioned above, revealing functional differences between PAPSS1 and PAPSS2
for DHEA sulfation by sulfotransferase SULT2A1. Three biological replicates
and their average are shown; each dot consists of at least three technical
replicates. Normally distributed data were analyzed by one-way ANOVA (p
value 0.001) and post-hoc Bonferroni tests (*, p 0.05; **, p 0.01) relative
to the control.
DHEA sulfation and PAPSS2–SULT2A1 interaction
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then carried out functional assays and found that siRNA-
mediated knockdown of SULT2A1 and PAPSS2 reduced
DHEA sulfation rates to 19 and 30%, respectively, whereas
depletion of PAPSS1 showed no discernable effect on DHEA
sulfation (Fig. 1D). This suggests nonoverlapping functionality
of the twohumanPAPS synthase proteinswith regard toDHEA
sulfation.
Enzymatic properties are very similar for both PAPS synthases
To determine whether different enzyme activities may
explain the above described differences in functionality, we
determined specific APS kinase activities of recombinant
PAPSS1 and PAPSS2 proteins in a coupled spectrophotometric
assay. APS kinase activity is known to be the rate-limiting step
of overall PAPS biosynthesis (12). Using two different enzyme
batches, performing multiple repeat measurements (Fig. 2A),
specific APS kinase activities appeared nondistinguishable,
34.9  17.0 nmol min1 mg1 for PAPSS1 and 31.6  10.6
nmol min1 mg1 for PAPSS2 (Table 1), in line with previous
findings (20).
The nucleotideAPS has been reported to be a highly effective
modulator of PAPS synthase proteins (4, 6). Hence, we deter-
mined binding affinity (KD) of a fluorescently labeled APS
derivative (mant-APS) to recombinant PAPS synthase proteins
(Fig. 2B). Theoretically, APS could bind to all six nucleotide-
binding sites of dimeric PAPS synthase proteins (6); but fitting
to the Hill equation resulted in very weak cooperativity with
Hill coefficients close to 1 (1.09  0.02 and 1.22  0.05 for
PAPSS1 and PAPSS2, respectively). Hence, data were fitted
assuming one binding site, resulting in apparent KD values of
13.2 0.3 and 23.0 1.6 M for PAPSS1 and PAPSS2, respec-
tively. Titrations of preformed PAPS synthase–mant-APS
complexes with APS confirmed that both nucleotides actually
bound to the same site(s) within the enzyme (Fig. 2C). We also
attempted to determine ATP sulfurylase activity; however, this
was hindered by considerable batch-to-batch variability in
PAPSS2 (data not shown). Without any significant differences
in the APS kinase activity of PAPSS1 and PAPSS2 and very
similar affinities for the modulating APS nucleotide, we con-
clude that differences in enzymatic activity cannot explain the
above described functional differences.
Cytosmic PAPSS2 supports SULT2A1 activity
To determine whether different cellular localization of PAPS
synthases might contribute to their functional differences, we
examined subcellular localization variants of PAPS synthases 1
and 2 with preferential nuclear or cytoplasmic localization (18)
for their ability to support DHEA sulfation by SULT2A1 (Fig.
3A). A nonsteroidogenic HEK293 cellular background with no
notable expression of these sulfation enzymes was used to co-
express PAPS synthase protein variants with cytoplasmic
SULT2A1; activity of this sulfation pathway was then tested in
DHEA sulfation assays (Fig. 3B). Cytoplasmic PAPSS1 expres-
sion only supported DHEA sulfation to 61% of WT protein
activity (conversion rates in (nmol DHEA/h) are given in Table
S2). Both nuclear PAPS synthases showed less DHEA sulfation
than the respectiveWTprotein (72 and 82% ofWT for PAPSS1
and PAPSS2, respectively). Only cytoplasmic PAPSS2 was as
effective in supporting DHEA sulfation as WT PAPSS2 (Fig.
3B). This effect of subcellular location on the ability of PAPSS2
to support DHEA sulfation by SULT2A1 led us to hypothesize
that these sulfation pathway proteins might physically interact.
Proximity ligation assays detect a protein–protein interaction
of PAPSS2 and SULT2A1
To test for a physical interaction between PAPSS2 and
SULT2A1, we employed PLA technology after demonstrating
that this putative interaction was not amenable to detection by
GFP-trap pulldown (Fig. S1A). Hypothesizing that the putative
Figure 2. APS kinase activity andAPSbindingproperties of humanPAPS
synthases.A, APS kinase activitywasmeasured in a coupled enzymatic assay
where ADP production is linked to NADH consumption via pyruvate kinase
and lactate dehydrogenase. 15 individual velocity measurements from two
different batches are shown. Please refer to Table 1 for the averaged specific
activity. B, APS binding studies where fluorescently labeled APS (1 M mant-
APS) was titrated with increasing concentrations of PAPS synthase protein.
Data were fitted assuming one binding site. C, back-titration of 1 M mant-
APS and 50 M PAPSS protein with increasing concentrations of APS. As
mant-APS canbedisplacedbyAPS, the fluorescentmantmoietydidnot inter-
fere with binding to the protein.
Table 1
Enzymatic characterization of human PAPS synthase isoforms
* Assuming a single nucleotide binding site.
** EC50 was measured in the presence of 50 M PAPSS protein and 1 M
mant-APS.
DHEA sulfation and PAPSS2–SULT2A1 interaction
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PAPSS2–SULT2A1 interaction is of transient character, we
employedPLA technology,which iswell-suited to capture tran-
sient interactions (22). DNA-linked secondary antibodies and a
linker oligo enable rolling circle amplification and signal gener-
ation (“foci”) only if the primary antibodies against SULT2A1
and PAPSS1/PAPSS2 have bound less than 40 nm apart. One
“focus” is assumed to correspond to one ligation event and the
average number of “foci per cell” is interpreted as binding
strength (23). PLA technology combined with automated cell,
nucleus, and foci recognition (Fig. 4A) allows for the analysis of
large numbers of cells per staining, more than 400 cells per
condition in our analysis. Foci per cell were clearly elevated in
the staining for PAPSS2 and SULT2A1, indicative of a physical
interaction between these proteins (Fig. 4B). Furthermore,
foci per cell were significantly higher for PAPSS2–SULT2A1
than for a corresponding staining of SULT2A1 and PAPSS1
(Fig. 4C).
SULT2A1 docks uniformly to the APS kinase domain of PAPSS2
To examine the newly detected PAPSS–SULT2A1 complex
on a molecular level, we used different available crystal struc-
tures of human SULT2A1 and structural information about
PAPS synthases for protein–protein docking using ClusPro
(24). This procedure revealed a novel protein–interaction
interface at the APS kinase domain of PAPSS2, where
SULT2A1 binds (Fig. 5A). Considering the almost perfect C2
symmetry of the APS kinase domain, we regarded two binding
sites as equivalent. Docking SULT2A1 to PAPSS1 resulted in
more diffuse complexes, as SULT2A1 populated additional
binding sites at the ATP sulfurylase of PAPSS1 (Fig. 5B). Statis-
tical analysis of the ensembles of docked complexes confirm
this observation (Fig. 5C). For PAPSS2, all amino acids found
most often at the interface with SULT2A1 cluster within the
APS kinase domain, whereas interacting amino acids of
PAPSS1 seem to be scattered over the entire protein (Fig. 5C).
Looking from the SULT2A1 side, the mode of binding to
PAPSS1 and PAPSS2 appears to be very similar, involving the
substrate-binding loops. One notable difference is that amino
acids from the cap, the major substrate-binding loop, are
involved in binding to PAPSS1, whereas these amino acids do
not play a role in binding to PAPSS2 (Fig. 5D).
The novel protein interactionmay be specific for PAPS
synthase 2 and the sulfotransferase SULT2A1 from hominids
Best scoring complexes were then subjected to local docking
and re-scoring using RosettaDock (25, 26). The resulting com-
plexes are described by their structural similarity to an average
complex (interface r.m.s. deviation) and a docking score repre-
senting an energy term (Fig. 6A). Docking of PAPSS2 and
SULT2A1 resulted in a cloud of docking experiments with a
clearly visible funnel toward low r.m.s. deviations and low
Rosetta energies (Fig. 6A). The corresponding PAPSS1/
SULT2A1 docking neither showed such a trend norwas it char-
acterized by similarly favorable Rosetta scores (Fig. 6A).
Figure3.CytoplasmicPAPSS2best supports cytoplasmicSULT2A1activ-
ity. A, HEK293 cells were transfected with cytoplasmic sulfotransferase
SULT2A1 as well as cytoplasmic (PAPSS1 K9A,K10A and PAPSS2 K6A,K8A) or
nuclear protein variants of PAPS synthases (PAPSS1 R111A,R112A and
PAPSS2 R101A,R102A) as EGFP fusion proteins. The different variants for
PAPSS1 are shown exemplarily; their localization was as described before
(18). 600 magnification. B, DHEA sulfation was assayed for these different
PAPS synthase variants. Each point represents the average from triplicate
measurements. Normally distributed datawere analyzed by one-wayANOVA
(p value  0.001) and post-hoc Bonferroni tests (*, p  0.05; **, p  0.01)
relative to the control.
Figure 4. A physical interaction of PAPSS2 and SULT2A1 detected by
proximity ligationassays.A, representative imagesof theproximity ligation
assay betweenPAPSS2 and SULT2A1 aswell as subsequent analysiswith Cell-
Profiler. Endogenous PAPS synthases and SULT2A1 were detected bymouse
monoclonal antibodies for PAPSS1 or PAPSS2 and a rabbit SULT2A1 poly-
clonal antibody in a HepG2 cell line. PLA analysis, including automated cell
and nucleus recognition and foci counting was carried out using CellProfiler
software. Cell nuclei were stained with Hoechst 33342 (blue); CellMask stain-
ing is shown in magenta. PLA foci are shown in white in the single channel
picture. In the output image of CellProfiler analysis edges of nuclei are repre-
sented in cyan, cell boarders in red, andPLA foci in yellow.B, CellProfiler results
for all other combinations. Negative controls were generated using only one
primary antibody at a time.600magnification for A and B. C, box-and-whis-
ker analysis of the PLA foci number per cell fromat least 400 cells pooled from
three independent experiments. Data were found to be not normally distrib-
uted; hence, one-way ANOVA (p value 0.001) and post hoc Bonferroni tests
(***, p 0.001) were performed after data were square root transformed.
DHEA sulfation and PAPSS2–SULT2A1 interaction
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To explore isoform specificity also for the sulfotransferase,
we repeated the entire docking procedure with the sulfotrans-
ferase SULT2B1 most closely related to SULT2A1 (51% amino
acid identity). Although PAPSS1 docking gave similar ensem-
bles both for SULT2A1 and SULT2B1, the PAPSS2–SULT2B1
pairing only gave nonpreferable scores (Fig. 6A). Best-scoring
complexes from each of these combinations were subjected to
molecular dynamics simulations. R.m.s. deviation trajectories
showed that all these complexes are stable and converge toward
an equilibrium state within the simulation time window (Fig.
S2), indicating that energy calculations were appropriate. Free
energy MM-PBSA calculations for all four complexes are
shown in Fig. 6B, van der Waals energies, polar solvation, and
SASA energy terms are roughly the same for all four combina-
tions. However, an electrostatics term of 1040 kJ/mol for
PAPSS2–SULT2A1 shows that electrostatics favor this interac-
tion; this energy term is about twice as high as those for
PAPSS1–SULT2A1 and PAPSS2–SULT2B1; PAPSS1–SULT2B1
is characterized by an even smaller electrostatics term (Fig. 6B).
Binding energies strongly favor PAPSS2 interactions over
PAPSS1 interactions, with both sulfotransferases (Fig. 6B).
Taken together, the interaction of PAPSS2 and SULT2A1 is
Figure 5. SULT2A1 docks to the APS kinase domain of PAPSS2. ClusPro
computational docking of three different SULT2A1 crystal structures (PDB
codes 1EFH, 3F3Y, and 4IFB) to structural models of PAPSS1 and PAPSS2. A,
PAPSS2–SULT2A1-docked complexes are shown. PAPSS2 APS kinase is
labeled; ATP sulfurylase is labeled and boxed. The two PAPSS2 dimeric sub-
units are gray and red. Two SULT2A1 molecules are depicted in yellow, ball
representation; contacting PAPSS2 at its APS kinase domain, sites 1 and 1. B,
corresponding representation of PAPSS1–SULT2A1 docking experiments. In
addition to sites 1 and 1, SULT2A1 contacts PAPSS1 also at the ATP sulfury-
lase domain. Color coding as in A, except the two PAPSS1 dimeric subunits,
which are gray and black. C and D, statistical analysis of all ClusPro docking
experiments, looking from the PAPS synthase side (C) and from the SULT2A1
side (D). Frequency of individual residues within 3 Å of the other protein was
analyzed for PDB 1EFH, 3F3Y, and 4IFB structures separately (30 dockings
each) and then averaged. Note the higher number of frequent protein con-
tacts within the APS kinase domain of PAPSS2, compared with the one from
PAPSS1. SULT2A1 contacted PAPS synthases mainly via its isoform-specific
substrate binding loops; one of these is regarded as “cap.”
Figure 6. The PAPSS2–SULT2A1 interaction may be isoform-specific. A,
SULT2B1 was selected as homologous sulfotransferase to analyze specificity
of the novel PAPSS2–sulfotransferase interaction. PAPS synthase–sulfurylase
dockingwas refined using RosettaDock. At least 10,000 docking experiments
are shown where the docking score was correlated with the interface r.m.s.
deviation value compared with the average complex. B, best solutions from
Rosettawere subjected toMD simulations (3 20 ns, see Fig. S2 for averaged
traces); MM-PBSA energies were derived therefrom, expressed as average
S.D. from three independent calculations.
DHEA sulfation and PAPSS2–SULT2A1 interaction
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mainly driven by electrostatic and entropic binding energy
terms.
An averaged the PAPSS2–SULT2A1 complex is shown in
Fig. 7A. An important feature is the composite nature of the
PAPSS2-binding site, both subunits contribute to the interac-
tion interface (Fig. 7B). To determine how general this interac-
tion might be, we looked at all interface amino acids of
SULT2A1 within an alignment of various mammalian
SULT2A1 species (Fig. 7C). There we found only two interface
amino acids to be specific to great apes, Thr85 andTyr238. These
amino acids were then mutated and the effects of these muta-
tions were assessed by Rosetta-based alanine scanning (27).
Figure 7. A PAPSS2–SULT2A1 protein interaction facilitates DHEA sulfation. A and B, molecular representation of a PAPSS2–SULT2A1 complex averaged
over 15nsofMDtime. Thedimeric PAPSS2 subunit proximal to SULT2A1 isdepicted ingray colorandwithmolecular surface representation; thedistant PAPSS2
subunit in red color and ribbon representation. SULT2A1 is drawn in yellow. Please note the composite nature of the PAPSS2-binding site. Amino acids on the
interface are shown in stick representation of the side chains and labeled accordingly. C, all SULT2A1 amino acids on the interface with PAPSS2 were
highlighted in an alignment of diverse mammalian SULT2A1 protein sequences. The only two interface amino acids that were specific to great apes are Thr85
and Tyr238 (depicted in blue in B). D, the PAPSS2–SULT2A1 interface was analyzed using Rosetta-based alanine scanning (27). Furthermore, the two great
ape-specific amino acidsweremutated to their nonhominoid counterparts. T85K resulted in a dramatic loss of stability of the complex. E, the hominid-specific
PAPSS2–SULT2A1 complex coincides with a higher DHEAS/DHEA ratio in gorilla, chimpanzee, and human. DHEAS/DHEA ratios are derived from Refs. 28
and 29.
DHEA sulfation and PAPSS2–SULT2A1 interaction
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Although the Y238F mutation only moderately compromised
the stability of the PAPSS2–SULT2A1 complex, the T85K
mutant destabilized the complex by more than 22 kJ/mol (Fig.
7D). Furthermore, the doublemutation also induced secondary
destabilizing effects at Asn17 (12 kJ/mol) as well as Arg166 and
Ile172 (5 kJ/mol each). We concluded that the PAPSS2–
SULT2A1 interaction was facilitated by amino acid exchanges
that only occurred in hominids. It thus correlates with the
higher DHEAS/DHEA ratios found in gorilla, chimpanzee, and
human (28), but not in other nonhominid primates or other
mammals (29, 30).
Discussion
Our knockdown studies of sulfation pathway enzymes in
human adrenal NCI-H295R1 cells, an established model of the
adrenal zona reticularis, the main site of DHEA sulfation by
SULT2A1, provide experimental evidence for a functional dif-
ference of PAPS synthases in the DHEA sulfation pathway.
PAPSS2 seems to be better able to support the sulfotransferase
SULT2A1 than its enzyme ortholog PAPSS1. Deviations in cat-
alytic properties or subcellular localization are not sufficient to
explain the leading role of PAPSS2 in this sulfation pathway. By
employing PLAs, we could detect a transient protein–protein
interaction between PAPS synthases and SULT2A1. The aver-
age number of foci per cell was significantly higher for PAPSS2
than for PAPSS1, indicative of a stronger interaction. Further-
more, molecular docking suggested a specific interaction of
SULT2A1 with the APS kinase domain of PAPSS2, whereas
analogous docking studies with PAPSS1 suggested a more dif-
fuse interaction pattern. This transient protein–protein inter-
action provides the mechanistic basis for the observed func-
tional differences between PAPSS1 and PAPSS2 with regard to
sulfation of DHEA by SULT2A1, a critical step in controlling
biosynthesis of active androgens in humans.
The protein–protein interaction described here is a novel
regulatory mechanism to confer directionality to sulfation
pathways (Fig. 7). This might be of most relevance in tissues
where both PAPS synthases are present at roughly similar levels
and where SULT2A1 is co-expressed with other cytoplasmic
sulfotransferases. The first condition is met in the adrenocorti-
cal NCI-H295R1 cell line of which we started, assuming our
real-time CT values roughly correlate with protein levels, we
had nearly identical PAPSS1 and PAPSS2 mRNA levels and
about 5-fold higher levels for SULT2A1 mRNA (Table S1).
Condition 2 is basically fulfilled in any of the tissues where
SULT2A1 is expressed: it is found strongly enriched in adrenal
cortex, duodenum, liver, and small intestine (31, 32). In all these
tissues, transcript abundance of SULT2A1 is higher than that of
PAPS synthases (31) and another sulfotransferase, SULT1A1, is
considerably co-expressed (31). In fact, cytoplasmic sulfotrans-
ferases are generally highly abundant, up to about 1% of total
soluble protein (“cytosolic fraction”) of intestine tissue was
reported to consist of the SULT enzymes SULT1A1/1A3, -1B1,
-2A1, and -1E1 (32); corresponding to 20–30 M sulfotrans-
ferase proteins. This means that there are many more PAPS-
utilizing enzymes than PAPS synthases and sulfotransferases
may even outnumber the PAPS cofactor itself (33), making a
transient and isoform-specific interaction highly relevant for a
functioning sulfation pathway.
In the crowded and complex environment of the living cell,
proteins tend to form higher-order, transient protein–protein
interactions (34), mostly remaining unnoticed or at least very
hard to study (35). These have been termed “quinary interac-
tions” (34), originally linked to an apparent conservation of iso-
electric points among homologous proteins (36). The two
human PAPS synthases PAPSS1 and PAPSS2 show very differ-
ent isoelectric points, 6.40 and 8.18, respectively (Table S4).
Taking the pI of SULT2A1 (pI  5.69) into account, a more
acidic (lower) value than most of the other cytoplasmic SULTs
(Table S4), a transient interaction between PAPSS2 and
SULT2A1, driven mainly by electrostatic interactions, is in
good agreement with what our MM-PBSA free energy calcula-
tions show (Fig. 6B). Counterintuitively, the PAPSS2 residues at
the SULT2A1 interface aremainly conserved in PAPSS1 (Table
S3). This suggests that the difference between PAPS synthase
isoforms may be caused by residues outside the protein inter-
face, possibly in the second or even third shell of the protein
(37).
A striking feature of the PAPSS2 interface with SULT2A1 is
its composite nature (Fig. 7, A and B). Within the PAPSS2
dimer, theN terminus of the distant subunit swaps over to form
the SULT2A1-binding site together with residues from the
proximal subunit, initially seen crystallographically for PAPSS1
(38). Then it was observed in protein dissociation/association
studies using fluorescently labeled PAPS synthases, PAPSS2
adopts this conformation about 2.5-fold quicker than PAPSS1
(20). An N terminally-truncated PAPSS1 protein, however,
does not show any different catalytic properties compared with
WT (38); parts of the protein responsible for quinary protein
interactions are obviously dispensable for the primary catalytic
function, as previously described for other quinary interactions
(34). This N-terminal peptide shows large displacement values
within the r.m.s. fluctuations calculations over the MD simula-
tion time (Table S3), indicating that its flexibilitymay play a role
for the PAPSS–SULT2A1 interaction; these r.m.s. fluctuation
values are also higher in PAPSS2 than in PAPSS1.
Analyzing RMSF data allows assessing the effect of the novel
PAPSS2–SULT2A1 protein interaction on the PAPS synthase.
Within dimeric PAPSS2, nearly all 61 residues at the SULT2A1
interface show lower r.m.s. fluctuation values in the proximity
to the sulfotransferase, compared with the corresponding
amino acid in the distant PAPS synthase subunit (Table S3),
which can be interpreted as stabilizing the otherwise fragile
protein (4). In the past, PAPS synthases have been purported to
have vastly differing specific activities (19), which actually was
only a 5-fold difference in kcat/Km values when treating bi-func-
tional PAPS synthases as Michaelis-Menten enzymes. For APS
kinase, which catalyzes the rate-limiting step in overall PAPS
biosynthesis, we did not observe this difference previously (20)
nor in the present study (Fig. 2A). Using fluorescently labeled
APS, we determined binding affinity of this nucleotide to PAPS
synthases that theoretically have six APS-binding sites per pro-
tein dimer. This apparent KD of APS is somewhat larger for
PAPSS2 (meaningAPS binds less tightly) than for PAPSS1. APS
was described as amodulator of PAPS synthase function (6) and
DHEA sulfation and PAPSS2–SULT2A1 interaction
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more of it would be needed for intracellular stabilization of
PAPSS2; making stabilization of PAPSS2 by a quinary interac-
tion a likely alternative.
Soluble sulfotransferases are believed to form dimers via an
unusually small binding interface spanning only 10 residues,
known as the KTVE motif (39), whereas dimer formation of
Golgi-localized sulfotransferases is mainly guided by their stem
regions (40, 41). Notably, dimer formation was reported to be
beneficial for sulfotransferase protein stability (42). This pre-
sumably “sticky” motif did not interfere with our docking
experiments; it was never found to be enriched at the PAPSS2–
SULT2A1 protein interface. In fact, the KTVE motif merges
into the PAPS-binding loop on the other side of the sulfotrans-
ferase molecule (43). Comparing trajectories of MD simula-
tions has been used in the past to approximate protein stability
(44, 45). The SULT2A1 MD trajectory for the PAPSS2–
SULT2A1 simulation certainly differs from the corresponding
PAPSS1 complex; suggesting the SULT2A1 molecule reaching
a stable state sooner (1 ns) in the presence of PAPSS2 than
PAPSS1 (Fig. S2). Furthermore, the average r.m.s. deviation of
SULT2A1 stays at around 3 Å in the presence of PAPSS2, but
further increases with PAPSS1. The presence of PAPSS2 seem-
ingly stabilizes the SULT2A1 protein. Sulfotransferases feature
three major substrate-binding “loops” based on early structural
characterization and sequence alignments (46, 47). For
SULT2A1, these would include Asp62–Arg74, Ser80–Gly83, and
Glu207–Ser251; however, most of these residues are within well-
defined secondary structure elements. In the three SULT2A1
crystal structures that we used for the present study (PDB codes
1EFH, 3F3Y, and 4IFB), a better description of the substrate-
binding site are the loops Pro14–Ser20, Glu79–Ile82, and
Asn136–Lys144 as well as the extended Tyr231–Gln244 loop that
covers the binding pocket (43). These substrate-binding loops
harbor all PAPSS2-contacting amino acids, except Glu73 and
Glu89. Glu89 is located on the other end of a short helix con-
taining the Glu79–Ile82 motif; Glu73 is part of a helical loop
spanning Ile71–Arg74 and just 5 Å apart from the substrate lith-
ocholic acid in the PDB 3F3Y structure. Being located in sub-
strate-binding loops, all these residues are at least 15 Å apart
from the 5-phosphorous atom of the 3-phosphoadenosine-
5-phosphate (PAP) cofactor. Thus, it seems unlikely that the
PAPSS2–SULT2A1 interaction facilitates cofactor transfer.
Instead, allosteric activation as recently described for
SULT1A1 (48) and/or protein stabilization may be the mecha-
nisms responsible for increased support of DHEA sulfation.
Recent amino acid exchanges within the substrate-binding
loops of SULT2A1 may make the PAPSS2–SULT2A1 interac-
tion specific to hominid primates only (Fig. 7) and this coin-
cides with significantly higher DHEAS/DHEA rates in the cir-
culation in anthropoid primates (28), contrasted to other
primates and other mammals (29, 30). Adaptive changes in
anthropoid proteomes have also been described for other
genes (49). One of these is another sulfotransferase,
SULT1A3, with a glutamic acid Glu146 within the substrate-
binding site making it a preferential catecholamine-sulfating
enzyme (50). SULT1A3 (and a duplicated gene named
SULT1A4 encoding the same protein) is the only sulfotrans-
ferase to have an acidic amino acid in this position.
SULT1A3/4 genes have only been found in higher primates
(New World monkeys, Old World monkeys, great apes, and
humans) so far (32, 51), suggesting a strong evolutionary
drive to develop this particular capacity specifically in higher
primates. Similar to this finding, the current study about
hominoid-specific facilitated DHEA sulfation may be rele-
vant for the validity of animal models of steroid sulfation
with significant implications for drug development relying
on the predictive quality of animal models.
In conclusion, we have elucidated the mechanistic basis for
the selective requirement for PAPSS2 in providing the sulfation
cofactor PAPS to the DHEA sulfotransferase SULT2A1. This
preference is explained by an isoform-specific, transient pro-
tein interaction of PAPSS2 and SULT2A1. SULT2A1 mainly
interacts with PAPSS2 via residues within its nonconserved
substrate-binding loops. Our analyses with PAPSS2 and the
closely related SULT2B1 sulfotransferase confirm that this
interaction is specific to SULT2A1. Isoform specificity on
the side of PAPS synthases arises from nonconserved sec-
ond- and third-shell residues causing differences in protein
flexibility and electrostatics. The PAPSS2–SULT2A1 inter-
action stabilizes the interaction partners and may even allos-
terically activate them. The current findings show a novel
regulatorymechanismwithin sulfation pathways and deepen
our understanding of PAPS synthase biochemistry; they may
help to better understand clinically observed PAPSS2 muta-
tions and even open new avenues to develop novel therapeu-
tic targets.
Materials andmethods
Cell culture
Adrenal NCI-H295R1 cells (kindly provided by Enzo Lalli,
Nice, France) were grown in Dulbecco’s modified Eagle’s medi-
um/F-12 (Gibco, Thermo Fisher, Waltham, MA) supple-
mented with 2.5% Nu-Serum, 1% ITS	 premix, and 1% peni-
cillin/streptomycin at 37 °C and 5% CO2. HEK293 cells were
propagated inminimal essentialmedium (Sigma)with 10%FCS
(PAA, GE Healthcare) and 1% penicillin/streptomycin (PAA,
GE Healthcare). HepG2 cells were maintained in RPMI (Invit-
rogen, Karlsruhe, Germany) with 10% FBS (Gibco, Thermo
Fisher) and 1% antibiotic-antimycotic (Gibco, Thermo Fisher)
in a humidified 5% CO2 atmosphere at 37 °C as recommended
by the American Type Culture Collection (ATCC). All cells
were verified to be mycoplasma-negative by PCR in regular
intervals.
Knockdown by siRNA in adrenal NCI-H295R1 cells
Adrenal NCI-H295R1 cells were transfected with the follow-
ing siRNA oligonucleotides (target (mRNA position) RNA
sequence (sense strand 5 to 3)): PAPSS1 (309) CCU GGU
UUG UCA UGG UAU U; (419) GCA UCG CAG AAG UUG
CUA A; (1380) GCA GGA UAC CCA UAA GCA A; PAPSS2,
(612) CCA GCU UUA UUU CUC CAU U; (899) GCA GAA
CAU UGU ACC CUA U; (1180) CCG UCU CUG CAG AGG
AUA A; SULT2A1 (169) GCA UAG CUU UCC CUA CUA U;
(622) GGU CAU GGU UUG ACC ACA U; (763) CCG AAG
AAC UGA ACU UAA U; control, GCC ACG UAA GAU GAG
UCA A; using the Viromer Blue transfection reagent (Lipoca-
DHEA sulfation and PAPSS2–SULT2A1 interaction
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lyx, Halle/Saale, Germany) according to the manufacturer’s
instructions. Knockdown efficiency was checked by quantita-
tive PCR using the following exon-spanning gene expression
assays, all TaqMan probes were labeled with 6-carboxyfluores-
cein (FAM) (Life Technologies, Thermo Fisher): Hs00234219_
m1 (SULT2A1); Hs00968937_m1 (PAPSS1); and Hs00989921_
m1 (PAPSS2). Expression levels were normalized to 18S rRNA
(HS99999901_s1). Protein expression was probed by West-
ern blotting using the polyclonal rabbit antibody ab38416
(Abcam, Cambridge, UK) or the monoclonal mouse antibody
SAB1100881 (Sigma) for SULT2A1, themAb ab56398 (Abcam,
Cambridge, UK) against PAPSS1 and the mAb ab56393
(Abcam) for PAPSS2. Equal loading was confirmed with horse-
radish peroxidase-linked mAb ab20272 (Abcam) against -ac-
tin. ECL (Millipore, Watford, UK) or anti-mouse ReadyTector
solution (CandorBioscience, Wangen im Allga¨u, Germany)
were used for detection.
Overexpression of PAPS synthase variants in HEK293 cells
PAPS synthase protein variants with preferred nuclear or
cytoplasmic localization have been described previously (18).
Mutating K9A,K10A in PAPSS1 or K6A,K8A in PAPSS2 dis-
rupts a conserved nuclear localization signal and results in pref-
erential cytoplasmic localization. Changing R111A,R112A in
PAPSS1 or R101A,R102A in PAPSS2, on the other hand, inac-
tivates a motif with nuclear export signal activity, resulting in
pronounced nuclear accumulation (18). Coding sequences for
all these protein variants without stop codons were NheI/
BamHI inserted in the eukaryotic expression vector pEGFP-N1
with a C-terminal EGFP fusion. HEK293 cells were transiently
co-transfected with these plasmids and a SULT2A1 expression
vector (14) using XtremeGene HP (Sigma) according to the
manufacturer’s protocol.
Enzymatic assays
The functionality of the DHEA sulfation pathway was
assessed by DHEA sulfation assays. NCI-H295R1 cells were
incubated with 250 nMDHEA and 0.2Ci of [3H]DHEA for 2 h
at 37 °C; all assays were performed in triplicate. Steroids were
extracted as previously described (13, 14), analyzed on a Lab-
logicAR2000 bioscanner, and identified by referring to simul-
taneously run labeled steroid standards. Sulfation activity after
transfection of scrambled control oligonucleotides was set to
100% activity. APS kinase activity was measured according to
the STRENDA convention as previously described (4, 20).
Briefly, ADP produced in the APS kinase-catalyzed reaction
was used by pyruvate kinase to convert phosphoenolpyruvate
to pyruvate. This is then converted by lactate dehydrogenase to
lactate. The concurrent conversion of NADH to NAD	 is fol-
lowed spectrophotometrically at 340 nm. APS kinase assays
were carried out at 20mMTris-HCl, pH 7.3, 100mMKCl, 5 mM
DTT, 2.5 mM ATP, 15 M APS, 10 mM MgCl2, 17.5/25 units of
LDH/protein kinase mix, 2 units of nuclease P1, 0.8 mM phos-
phoenolpyruvate, 0.3 mM NADH, 30 g/ml of PAPS. For APS
ligand binding studies, mant-APS was obtained from Jena Bio-
science (Jena, Germany) where an N-methylanthraniloyl fluo-
rophore was esterified to the (2,3)-hydroxyl of the ribosemoi-
ety. Mant-APS was at a concentration of 1 M for protein
binding studies; for back-titration with label-free APS, 50 M
protein was added.
Immunofluorescence
For immunofluorescence staining, human HepG2 cells were
seeded in 35-mm glass bottom dishes (MatTek, Ashland, MA).
Cells were fixed with 4% Histofix (Carl Roth, Karlsruhe, Ger-
many) for 20 min at room temperature, followed by blocking
and permeabilization with PBS containing 5% normal serum
(Dako, Glostrup, Denmark) and 0.3% Triton X-100 (Appli-
Chem, Darmstadt, Germany). Immunostaining was performed
overnight at 4 °C with primary antibodies specific for PAPSS1
or PAPSS2 (both Abcam, Cambridge, UK) and SULT2A1
(Sigma) diluted 1:200 in PBS containing 1% BSA (Carl Roth,
Karlsruhe, Germany) and 0.3% Triton X-100. Following several
washing steps, secondary antibodies labeled with Alexa Fluor
488 and Alexa Fluor 568 (Life Technologies, Thermo Fisher)
were incubated for 1 h at room temperature. DNA was stained
withHoechst 33342 (AppliChem,Darmstadt, Germany) in PBS
for 15 min at room temperature. Images (Fig. S1B) were taken
with a Leica SP8 confocal microscope equipped with a HCX PL
Apo CS 63.0  1.20 water UV objective, a sensitive hybrid
detector and Diode 405, Argon and DPSS561 lasers (Leica,
Wetzlar, Germany).
Proximity ligation assays
Interactions of sulfation pathway proteins were tested for by
PLA technology. Human HepG2 cells were grown, fixed,
blocked, and permeabilized as described above. Cells were then
incubated overnight at 4 °Cwith primary antibodies specific for
PAPSS1 or PAPSS2 (both fromAbcam) and SULT2A1 (Sigma)
diluted 1:200 in PBS containing 1% BSA (Carl Roth, Karlsruhe,
Germany) and 0.3% Triton X-100. PLA was conducted using
theDuolink In Situ PLAprobes and detection reagents (Sigma),
following the instructions of the manufacturer. DNA was
stained with Hoechst 33342 (AppliChem, Darmstadt, Ger-
many) in PBS for 15min at room temperature; entire cells were
stained withHCSCellMaskDeep Red Stain (Life Technologies,
Thermo Fisher) in PBS for 15min at room temperature. Images
were taken with a Leica SP8 confocal microscope equipped
with a HCX PL Apo CS 63.0 1.20 water UV objective, a sen-
sitive hybrid detector and Diode 405, Argon and DPSS561
lasers, and further analyzed with CellProfiler (52, 53). We
noticed that the overall intensity of the PLA signal inversely
correlated with cell density: when grown more densely, lower
PLA signal intensities were observed. However, cell density did
not affect foci number.
Structural analysis andmolecular docking
Full all-atommodels of PAPSS1 and PAPSS2 were built with
the MMMserver (54) using the crystal structures of both the
isolated kinase domain and an APS complex of full-length
PAPSS1 (PDB 2OFX and 1XNJ, respectively). Homology build-
ing also for PAPSS1 ensured that we used comparable struc-
tures of PAPSS1 and PAPSS2 coherently throughout this study.
To elucidate the binding sites and investigate themode of bind-
ing, these optimized models of both PAPSS1 and PAPSS2 were
docked to three different SULT2A1 structures (PDB codes
DHEA sulfation and PAPSS2–SULT2A1 interaction
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3F3Y, 4IFB, and 1EFH) and to SULT2B1 (PDB code 1Q1Q) by
the rigid-body protein–protein docking software ClusPro.
PAPS synthase and sulfotransferase structures were submitted
as receptor and ligand, respectively, to the ClusPro protein–
protein docking server using default settings (24). The top 1000
lowest energy-docking poses of aforementioned complexes are
grouped into 30 clusters and the lowest energy poses of each
cluster form the final 30 docking poses. Docking results were
scored using the standard ClusPro “balanced docking score,”
where all electrostatic, hydrophobic, and van derWaals	 Elec
coefficients are taken into account. All 30 ClusPro poses where
further filtered by populating the top amino acid contacts
within all complex structures. To analyze the involvement of
each amino acid in the protein–protein interaction interfaces,
we calculated the prevalence of interface interactions for the
receptor PAPSS residues with contacts made to the ligand
SULTs in all dockings.
For each PAPS synthase/sulfotransferase system, MD simu-
lations were run as the following. The protein complex was
inserted in a dodecahedric box of TIP3P water molecules
ensuring a minimum distance to the box edges of 10 Å. The
proper amount ofNa	 andCl ionswas added to reach an ionic
concentration of 150 mM and ensure final neutral systems. A
steepest-descent minimization was applied to relax the solvent
molecules around the solute. The equilibration was performed
in two steps: the system was at first thermalized up to 300 K
coupling the protein and the solvent to a V-rescale thermostat
(t  0.1 ps) in the canonical ensemble (NVT). Then, we
switched to the NPT statistical ensemble, performing 100 ps of
MD at 300 K, coupling the system with a Parrinello-Rahman
barostat (p  2 ps). After this initial phase, the system was
submitted for production MD simulations. Production runs
were carried out in the NPT (p  1 bar, T  300 K) statistical
ensemble. All bonds were constrained with LINCS (55), allow-
ing to use a time step set of 2 fs. Periodic boundary conditions
were applied to the systems in all directions. The PMEmethod
was used to evaluate long-range electrostatic interactions (PME
order 4, Fourier spacing 0.12), and a cutoff of 10Åwas used
to account for the van der Waals interactions. Coordinates of
the systems were collected every 2 ps. All MD simulations were
carried out with GROMACS-5 using the Gromos 53A6 force
field on GPU/CPU machines. The length of the MD simula-
tionswas 20 ns, and standardMDwere used forMM-PBSA and
for all analysis. Binding free energy were calculated using the
GROMACS tool g_mmpbsa (56).
Data analysis
Enzyme kinetics and titration data were analyzed and visual-
ized usingGraphPad Prism. Densitometric analysis of bands on
Western blots was carried out with GelAnalyzer. Visualization
of protein structures and structural models was done in PyMol,
VMD, andYASARA.Normality of any datawere checked for by
visual inspection of histogram plots as well as with Ryan-Joiner
and D’Agostino-Person tests. Pairwise and multiple compari-
sons of normally distributed data were done with two-tailed
unpaired t tests and one-way ANOVA as well as post hoc Bon-
ferroni tests, respectively. All statistical analyses were carried
out with the Analysis ToolPak-VBA (Microsoft) or Minitab 17.
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